Interventional Cardiology

At Biosensors, we strive to make an impact in patients’ lives by continually investing in and developing pioneering medical technology. Being at the forefront of new and innovative solutions helps us respond to the changing needs of the interventional cardiology market. We are the first company to offer a commercially available abluminal drug-eluting stent with a biodegradable limus technology.

History of Firsts

We have demonstrated and proven our commitment to innovation in interventional cardiology as we were the:

  • First cardiology device company to develop a proprietary drug specifically designed for coronary stent use — BA9™ (Biolimus A9™) the compound is proprietary to Biosensors and is not licensed from a pharmaceutical company
  • First company to successfully develop and launch an abluminal biodegradable polymer DES with a coating absorbed after 6 to 9 months*.
  • First company to sponsor a randomized head-to-head comparison against a sirolimus eluting stent in an all-comers setting.
  • First company to prove non-inferiority on a clinical endpoint against CYPHER® SELECT™1

Our interventional cardiology products are designed
to optimize your patient outcomes

Drug-Eluting Stents (DES)

Our new generation drug-eluting stents were created using the most advanced medical technology in its field. They offer patients many benefits by combining:

BioMatrix Flex™

BA9™ with Biodegradable Polymer and Juno™ Stent Platform

  • Proven safety of a DES with
    • An abluminal coating that promotes an endothelial coverage similar to a bare metal stent (BMS), provides more targeted drug release and reduces the systemic exposure
    • A biodegradable polymer that is absorbed after 6 to 9 months*
  • Proven efficacy of our drug, BA9™, that has 10 times more lipophilicity than sirolimus, resulting in a more targeted release to the vessel wall
  • Enhanced deliverability** with advanced stent design



BioMatrix™
BA9™ with Biodegradable Polymer and S-Stent™ Platform

Bare Metal Stents

Gazelle™

Based on the advanced design technology behind our proprietary S-Stent™ platform, Gazelle™3 is our bare metal stent (BMS) that provides cardiologists with:

  • Flexible stent design with the Quatrature Link™ technology for excellent deliverability

Balloon Dilation Catheter

Powerline™

Biosensors’ balloon dilatation catheter achieves the right balance of push-track-cross to meet clinical needs

  • The MultiPleat™ folding technology provides excellent cross and re-cross properties to facilitate use in complex procedures.

 

* In vivo testing in porcine model demonstrates abluminal coating is absorbed after 6 to 9 months - Data on file at Biosensors Intl

** Deliverability defined as a combination of flexibility, trackability and pushability

1.
CYPHER® SELECT™ is a trademark of Cordis Corporation.
3.
Commercialized under the name S-Stent™ in Japan.

CAUTION: The law restricts these devices to sale by or on the order of a physician. Indications, contraindications, warnings and instructions for use can be found in the product labeling supplied with each device.
Biosensors’ interventional cardiology products, including BioMatrix™, Gazelle™, S-Stent™, Powerline™, Quadrature Link™ and MultiPleat™, are not available for sale in the United States and certain other countries.
BioMatrix Flex, BioMatrix, Juno, Biolimus A9 and BA9 are trademarks or registered trademarks of Biosensors International Group, Ltd. in the United States and other countries. All cited trademarks are the property of their respective owners.